MedTrace Logo

A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma

NCT03663114 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 713

Last updated 2021-01-22

No results posted yet for this study

Summary

This study is a post-marketing observational study of lenvatinib in participants with unresectable hepatocellular carcinoma. The primary objective of this study is assessment of risk factors for hepatic encephalopathy.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Lenvatinib

Lenvatinib capsule

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-02
Primary Completion
2020-02-20
Completion
2020-02-20

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03663114 on ClinicalTrials.gov